Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EPS (Weighted Average and Diluted) (2016 - 2026)

Rockwell Medical filings provide 15 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.01 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 75.0% to -$0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.15, a 200.0% decrease, with the full-year FY2025 number at -$0.15, down 400.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Rockwell Medical, up from -$0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.04 in Q3 2024 to a low of -$1.04 in Q4 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.06 (2023), compared with a mean of -$0.3.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 1055.56% in 2021 and later skyrocketed 157.14% in 2024.
  • Rockwell Medical's EPS (Weighted Average and Diluted) stood at -$1.04 in 2021, then soared by 95.19% to -$0.05 in 2022, then increased by 0.0% to -$0.05 in 2023, then rose by 20.0% to -$0.04 in 2024, then surged by 75.0% to -$0.01 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.01 (Q4 2025), -$0.05 (Q3 2025), and -$0.05 (Q2 2025) per Business Quant data.